{
"instance": {
"gluc_s1.htm": {
"axisCustom": 0,
"axisStandard": 14,
"contextCount": 143,
"dts": {
"calculationLink": {
"local": [
"gluc-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"gluc-20220630_def.xml"
]
},
"inline": {
"local": [
"gluc_s1.htm"
]
},
"labelLink": {
"local": [
"gluc-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"gluc-20220630_pre.xml"
]
},
"schema": {
"local": [
"gluc-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
"https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
"https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
"https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
"https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
]
}
},
"elementCount": 315,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2022": 79,
"http://glucosehealth.com/20220630": 18,
"http://xbrl.sec.gov/dei/2022": 3,
"total": 100
},
"keyCustom": 60,
"keyStandard": 150,
"memberCustom": 22,
"memberStandard": 13,
"nsprefix": "gluc",
"nsuri": "http://glucosehealth.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"strong",
"p",
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "000001 - Document - Cover",
"role": "http://glucosehealth.com/role/Cover",
"shortName": "Cover",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"strong",
"p",
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000010 - Disclosure - NOTES PAYABLE",
"role": "http://glucosehealth.com/role/NotesPayable",
"shortName": "NOTES PAYABLE",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000011 - Disclosure - FEDERAL INCOME TAX",
"role": "http://glucosehealth.com/role/FederalIncomeTax",
"shortName": "FEDERAL INCOME TAX",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000012 - Disclosure - COMMITMENTS CONTINGENCIES",
"role": "http://glucosehealth.com/role/CommitmentsContingencies",
"shortName": "COMMITMENTS CONTINGENCIES",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:CustomerConcentrationsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000013 - Disclosure - CUSTOMER CONCENTRATIONS",
"role": "http://glucosehealth.com/role/CustomerConcentrations",
"shortName": "CUSTOMER CONCENTRATIONS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:CustomerConcentrationsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2021-01-01to2021-12-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:RecoveryOfRetailerChargebacksTextblock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000014 - Disclosure - RECOVERY OF RETAILER CHARGEBACKS",
"role": "http://glucosehealth.com/role/RecoveryOfRetailerChargebacks",
"shortName": "RECOVERY OF RETAILER CHARGEBACKS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2021-01-01to2021-12-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:RecoveryOfRetailerChargebacksTextblock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000015 - Disclosure - RELATED PARTY TRANSACTIONS",
"role": "http://glucosehealth.com/role/RelatedPartyTransactions",
"shortName": "RELATED PARTY TRANSACTIONS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000016 - Disclosure - SUBSEQUENT EVENTS",
"role": "http://glucosehealth.com/role/SubsequentEvents",
"shortName": "SUBSEQUENT EVENTS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:UseOfEstimates",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
"role": "http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
"shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:UseOfEstimates",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"us-gaap:EarningsPerSharePolicyTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:ScheduleOfPotentialDilutiveSecuritiesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
"role": "http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesTables",
"shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:EarningsPerSharePolicyTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:ScheduleOfPotentialDilutiveSecuritiesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000019 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
"role": "http://glucosehealth.com/role/StockholdersEquityTables",
"shortName": "STOCKHOLDERS EQUITY (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "000002 - Statement - BALANCE SHEETS",
"role": "http://glucosehealth.com/role/BalanceSheets",
"shortName": "BALANCE SHEETS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000020 - Disclosure - FEDERAL INCOME TAX (Tables)",
"role": "http://glucosehealth.com/role/FederalIncomeTaxTables",
"shortName": "FEDERAL INCOME TAX (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"gluc:CustomerConcentrationsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:SalesAndRetailerCustomerSalesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000021 - Disclosure - CUSTOMER CONCENTRATIONS (Tables)",
"role": "http://glucosehealth.com/role/CustomerConcentrationsTables",
"shortName": "CUSTOMER CONCENTRATIONS (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"gluc:CustomerConcentrationsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gluc:SalesAndRetailerCustomerSalesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000022 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)",
"role": "http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R23": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"gluc:ScheduleOfPotentialDilutiveSecuritiesOutstanding",
"us-gaap:EarningsPerSharePolicyTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
"role": "http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails",
"shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"gluc:ScheduleOfPotentialDilutiveSecuritiesOutstanding",
"us-gaap:EarningsPerSharePolicyTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AdvertisingExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
"role": "http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
"shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AdvertisingExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesIssued",
"reportCount": 1,
"unitRef": "Shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000025 - Disclosure - STOCKHOLDERS DEFICIT (Details)",
"role": "http://glucosehealth.com/role/StockholdersDeficitDetails",
"shortName": "STOCKHOLDERS DEFICIT (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30_us-gaap_SeriesAPreferredStockMember",
"decimals": "INF",
"lang": null,
"name": "gluc:PreferredStocksParValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "USDPShares",
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"gluc:ScheduleOfWarrantGrantsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2021-12-31_gluc_WarrantsMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unitRef": "Shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000026 - Disclosure - STOCKHOLDERS DEFICIT (Details 1)",
"role": "http://glucosehealth.com/role/StockholdersDeficitDetails1",
"shortName": "STOCKHOLDERS DEFICIT (Details 1)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"gluc:ScheduleOfWarrantGrantsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2019-12-31_gluc_WarrantsMember",
"decimals": "0",
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesAuthorized",
"reportCount": 1,
"unitRef": "Shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000027 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative)",
"role": "http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"shortName": "STOCKHOLDERS DEFICIT (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2020-01-01to2020-12-31",
"decimals": "0",
"lang": null,
"name": "us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2020-12-31",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:InterestPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000028 - Disclosure - NOTES PAYABLE (Details Narrative)",
"role": "http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"shortName": "NOTES PAYABLE (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2020-12-31",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:InterestPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLossCarryforwards",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000029 - Disclosure - FEDERAL INCOME TAX (Details)",
"role": "http://glucosehealth.com/role/FederalIncomeTaxDetails",
"shortName": "FEDERAL INCOME TAX (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"lang": null,
"name": "gluc:TemporaryDifferences",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:TradeAndOtherAccountsReceivablePolicy",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "000003 - Statement - BALANCE SHEETS (Parenthetical)",
"role": "http://glucosehealth.com/role/BalanceSheetsParenthetical",
"shortName": "BALANCE SHEETS (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "INF",
"lang": null,
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "USDPShares",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000030 - Disclosure - FEDERAL INCOME TAX (Details 1)",
"role": "http://glucosehealth.com/role/FederalIncomeTaxDetails1",
"shortName": "FEDERAL INCOME TAX (Details 1)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "gluc:EffectiveTaxRateForFederalIncomeTaxes",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000031 - Disclosure - FEDERAL INCOME TAX (Details Narrative)",
"role": "http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative",
"shortName": "FEDERAL INCOME TAX (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "gluc:EffectiveTaxRateForFederalIncomeTaxes",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"gluc:SalesAndRetailerCustomerSalesTableTextBlock",
"gluc:CustomerConcentrationsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "gluc:SalesAndRetailerCustomerSales",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000032 - Disclosure - CUSTOMER CONCENTRATIONS (Details)",
"role": "http://glucosehealth.com/role/CustomerConcentrationsDetails",
"shortName": "CUSTOMER CONCENTRATIONS (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"gluc:SalesAndRetailerCustomerSalesTableTextBlock",
"gluc:CustomerConcentrationsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "gluc:SalesAndRetailerCustomerSales",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"p",
"gluc:CustomerConcentrationsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30_srt_MaximumMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:DeferredRevenueRevenueRecognized1",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000033 - Disclosure - CUSTOMER CONCENTRATIONS (Details Narrative)",
"role": "http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative",
"shortName": "CUSTOMER CONCENTRATIONS (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"gluc:CustomerConcentrationsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30_srt_MaximumMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:DeferredRevenueRevenueRecognized1",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"p",
"gluc:RecoveryOfRetailerChargebacksTextblock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2021-01-01to2021-12-31",
"decimals": "0",
"first": true,
"lang": null,
"name": "gluc:RecognizedRecoveryOfRetailerChargebacks",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000034 - Disclosure - RECOVERY OF RETAILER CHARGEBACKS (Details Narrative)",
"role": "http://glucosehealth.com/role/RecoveryOfRetailerChargebacksDetailsNarrative",
"shortName": "RECOVERY OF RETAILER CHARGEBACKS (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"gluc:RecoveryOfRetailerChargebacksTextblock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2021-01-01to2021-12-31",
"decimals": "0",
"first": true,
"lang": null,
"name": "gluc:RecognizedRecoveryOfRetailerChargebacks",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30_gluc_CEOCFOMember_gluc_OneJulyTwoThousendTwentyOneMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:DueFromRelatedParties",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000035 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
"role": "http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30_gluc_CEOCFOMember_gluc_OneJulyTwoThousendTwentyOneMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:DueFromRelatedParties",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesIssued",
"reportCount": 1,
"unitRef": "Shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
"role": "http://glucosehealth.com/role/SubsequentEventsDetailsNarrative",
"shortName": "SUBSEQUENT EVENTS (Details Narrative)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:SubsequentEventsTextBlock",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2022-03-22_gluc_RegisteredMember_gluc_TwoIndependentDirectorsMember",
"decimals": "0",
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-04-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:Revenues",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "000004 - Statement - STATEMENTS OF OPERATIONS",
"role": "http://glucosehealth.com/role/StatementsOfOperations",
"shortName": "STATEMENTS OF OPERATIONS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-04-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:Revenues",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:SharesIssued",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "000005 - Statement - STATEMENTS OF SHAREHOLDERS' EQUITY",
"role": "http://glucosehealth.com/role/StatementsOfShareholdersEquity",
"shortName": "STATEMENTS OF SHAREHOLDERS' EQUITY",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:SharesIssued",
"reportCount": 1,
"unique": true,
"unitRef": "Shares",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "000006 - Statement - STATEMENTS OF CASH FLOWS",
"role": "http://glucosehealth.com/role/StatementsOfCashFlows",
"shortName": "STATEMENTS OF CASH FLOWS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2021-01-01to2021-12-31",
"decimals": "0",
"lang": null,
"name": "us-gaap:AmortizationOfIntangibleAssets",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION",
"role": "http://glucosehealth.com/role/OrganizationAndBasisOfPresentation",
"shortName": "ORGANIZATION AND BASIS OF PRESENTATION",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
"role": "http://glucosehealth.com/role/SummaryOfSignificantAccountingPolicies",
"shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "000009 - Disclosure - STOCKHOLDERS EQUITY",
"role": "http://glucosehealth.com/role/StockholdersEquity",
"shortName": "STOCKHOLDERS EQUITY",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "gluc_s1.htm",
"contextRef": "From2022-01-01to2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 35,
"tag": {
"dei_AmendmentDescription": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of changes contained within amended document.",
"label": "Amendment Description"
}
}
},
"localname": "AmendmentDescription",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "stringItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address Address Line 1"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address Address Line 2"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address City Or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address State Or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityExTransitionPeriod": {
"auth_ref": [
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
"label": "Entity Ex Transition Period"
}
}
},
"localname": "EntityExTransitionPeriod",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation State Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://glucosehealth.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"gluc_AccruedInterest": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "[Accrued interest]",
"verboseLabel": "Accrued interest"
}
}
},
"localname": "AccruedInterest",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_AccruedInterestCurrent": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 10.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Accrued interest"
}
}
},
"localname": "AccruedInterestCurrent",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"gluc_AdditionalBorrowed": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Additional borrowed"
}
}
},
"localname": "AdditionalBorrowed",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Potential dilutive securities outstanding]",
"verboseLabel": "Potential dilutive securities outstanding"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"gluc_AprilTwentyTwoThousandsTwelveMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "April 20, 2012 [Member]"
}
}
},
"localname": "AprilTwentyTwoThousandsTwelveMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_AprilTwoThousendNineteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "April 2019 [Member]"
}
}
},
"localname": "AprilTwoThousendNineteenMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_AugustFourTwoThousandsFourteenThroughAprilOneTwoThousandsSixteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "August 4, 2014 through April 1, 2016 [Member]"
}
}
},
"localname": "AugustFourTwoThousandsFourteenThroughAprilOneTwoThousandsSixteenMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_CEOCFOMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CEO/CFO [Member]",
"verboseLabel": "CEO/CFO [Member]"
}
}
},
"localname": "CEOCFOMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_CommitmentsContingenciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "COMMITMENTS CONTINGENCIES"
}
}
},
"localname": "CommitmentsContingenciesAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_CommonStockWarrantIssuedForServices": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Common stock warrant issued for services"
}
}
},
"localname": "CommonStockWarrantIssuedForServices",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"gluc_ConversionOfNotesPayableAndAccruedInterestToCommonStock": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Conversion of notes payable and accrued interest to common stock"
}
}
},
"localname": "ConversionOfNotesPayableAndAccruedInterestToCommonStock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"gluc_ConversionOfSeriesBPreferredStockToCommonStock": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Conversion of Series B preferred stock to Common stock"
}
}
},
"localname": "ConversionOfSeriesBPreferredStockToCommonStock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"gluc_ConvertibleNotesPayableRelatedPartyCurrent": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 9.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Convertible note payable, related party"
}
}
},
"localname": "ConvertibleNotesPayableRelatedPartyCurrent",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"gluc_ConvertibleNotesPayableRelatedPartyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Convertible notes payable, related party [Member]"
}
}
},
"localname": "ConvertibleNotesPayableRelatedPartyMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_CustomerConcentrationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CUSTOMER CONCENTRATIONS"
}
}
},
"localname": "CustomerConcentrationsAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_CustomerConcentrationsTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[CUSTOMER CONCENTRATIONS]",
"verboseLabel": "CUSTOMER CONCENTRATIONS"
}
}
},
"localname": "CustomerConcentrationsTextBlock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrations"
],
"xbrltype": "textBlockItemType"
},
"gluc_DecemberTenTwoThousandsThirteenMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "December 10, 2013 [Member]"
}
}
},
"localname": "DecemberTenTwoThousandsThirteenMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_DirectorFee": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Director fee"
}
}
},
"localname": "DirectorFee",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_DividendsDescription": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Dividends description"
}
}
},
"localname": "DividendsDescription",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"gluc_DividendsPaidToPreferredStockHolders": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Dividends paid to preferred stock holders"
}
}
},
"localname": "DividendsPaidToPreferredStockHolders",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"gluc_DividendsPreferredsStock": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "[Dividends to preferred stock holders]",
"negatedLabel": "Dividends to preferred stock holders",
"verboseLabel": "Dividends to preferred stock holders"
}
}
},
"localname": "DividendsPreferredsStock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"gluc_EarningPerShareBasicAndDiluted": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "NET INCOME (LOSS) PER SHARE - BASIC AND DILUTED"
}
}
},
"localname": "EarningPerShareBasicAndDiluted",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "perShareItemType"
},
"gluc_EffectiveIncomeTaxRateReconciliationTemporaryDifferences": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Temporary differences]",
"verboseLabel": "Temporary differences"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationTemporaryDifferences",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails1"
],
"xbrltype": "percentItemType"
},
"gluc_EffectiveTaxRateForFederalIncomeTaxes": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Effective tax rate for federal income taxes"
}
}
},
"localname": "EffectiveTaxRateForFederalIncomeTaxes",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative"
],
"xbrltype": "percentItemType"
},
"gluc_EffectiveincometaxratereconciliationPermanentDifferences": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Permanent differences]",
"verboseLabel": "Permanent differences"
}
}
},
"localname": "EffectiveincometaxratereconciliationPermanentDifferences",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails1"
],
"xbrltype": "percentItemType"
},
"gluc_EffectiveincometaxratereconciliationValuationAllowance": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Valuation allowance]",
"verboseLabel": "Valuation allowance"
}
}
},
"localname": "EffectiveincometaxratereconciliationValuationAllowance",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails1"
],
"xbrltype": "percentItemType"
},
"gluc_EndUserSalesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "End-User Sales"
}
}
},
"localname": "EndUserSalesMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetails"
],
"xbrltype": "domainItemType"
},
"gluc_FederalAndStateMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Federal And State [Member]"
}
}
},
"localname": "FederalAndStateMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_GainLossOnForgivenessOfAccountsPayable": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 7.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 15.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Gain on forgiveness of accounts payable",
"negatedLabel": "Gain on forgiveness of accounts payable"
}
}
},
"localname": "GainLossOnForgivenessOfAccountsPayable",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows",
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"gluc_GlucoseHealthIncMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Glucose Health, Inc [Member]"
}
}
},
"localname": "GlucoseHealthIncMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_IndividualOneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Individual One [Member]"
}
}
},
"localname": "IndividualOneMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_IndividualTwoMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Individual Two [Member]"
}
}
},
"localname": "IndividualTwoMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_IntellectualAssetsNetNoncurrent": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Intellectual assets, net of accumulated amortization"
}
}
},
"localname": "IntellectualAssetsNetNoncurrent",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"gluc_IssuanceOfCommonStockForPrepaidMarketingExpense": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Issuance of common stock for prepaid marketing expense"
}
}
},
"localname": "IssuanceOfCommonStockForPrepaidMarketingExpense",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"gluc_IssuanceOfCommonStockForServices": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 5.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Common stock issued for services"
}
}
},
"localname": "IssuanceOfCommonStockForServices",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"gluc_IssuedInvoicesPurchaseOrdersForShipmentsOfGlucodown": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Issued invoices purchase orders for shipments of GLUCODOWN"
}
}
},
"localname": "IssuedInvoicesPurchaseOrdersForShipmentsOfGlucodown",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_JuneTwoThousendTwentyOneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "June 2021 [Member]"
}
}
},
"localname": "JuneTwoThousendTwentyOneMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_NetIncomeLossPerShareAttributableToCommonShareholdersBasicAndDiluted": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO COMMON SHAREHOLDERS - BASIC AND DILUTED"
}
}
},
"localname": "NetIncomeLossPerShareAttributableToCommonShareholdersBasicAndDiluted",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "perShareItemType"
},
"gluc_NoteRepaidInCash": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Note repaid in cash"
}
}
},
"localname": "NoteRepaidInCash",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_NoteRepaidInFullByIssuingShares": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note repaid in full by issuing shares"
}
}
},
"localname": "NoteRepaidInFullByIssuingShares",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"gluc_NotesPayableDetailsNarrativeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "NOTES PAYABLE (Details Narrative)"
}
}
},
"localname": "NotesPayableDetailsNarrativeAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_NotesToFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "ORGANIZATION AND BASIS OF PRESENTATION"
}
}
},
"localname": "NotesToFinancialStatementsAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_NumberOfPromissoryNotes": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Number of promissory notes"
}
}
},
"localname": "NumberOfPromissoryNotes",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "integerItemType"
},
"gluc_OneAprlTwoThousendTwenttytwoMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "April 1, 2022 [Member]"
}
}
},
"localname": "OneAprlTwoThousendTwenttytwoMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_OneJulyTwoThousendTwentyOneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "July 1, 2021 [Member]"
}
}
},
"localname": "OneJulyTwoThousendTwentyOneMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_OrganizationAndBasisOfPresentationDetailsNarrativeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)"
}
}
},
"localname": "OrganizationAndBasisOfPresentationDetailsNarrativeAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_OriginallyDueDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Originally due date"
}
}
},
"localname": "OriginallyDueDate",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "dateItemType"
},
"gluc_OtherIncomeExpenseAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "OTHER INCOME (EXPENSE)"
}
}
},
"localname": "OtherIncomeExpenseAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"gluc_OtherInterestIncomeExpenseNonCashItems": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 12.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Interest income (expense), non-cash item"
}
}
},
"localname": "OtherInterestIncomeExpenseNonCashItems",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"gluc_OtherNotesPayableMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other notes payable [Member]"
}
}
},
"localname": "OtherNotesPayableMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_PermanentDifferences": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Permanent differences"
}
}
},
"localname": "PermanentDifferences",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails"
],
"xbrltype": "monetaryItemType"
},
"gluc_PotentialBonuses": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "[Potential bonuses]",
"verboseLabel": "Potential bonuses"
}
}
},
"localname": "PotentialBonuses",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_PreferredStockAuthorized": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Preferred stock, shares authorized]",
"verboseLabel": "Preferred stock, shares authorized"
}
}
},
"localname": "PreferredStockAuthorized",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"gluc_PreferredStockSeriesBToEMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Preferred Stock Series B - E"
}
}
},
"localname": "PreferredStockSeriesBToEMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "domainItemType"
},
"gluc_PreferredStockSharesCanceled": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Preferred Stock shares canceled"
}
}
},
"localname": "PreferredStockSharesCanceled",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"gluc_PreferredStockSharesSeriesAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Preferred Stock Series A"
}
}
},
"localname": "PreferredStockSharesSeriesAMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "domainItemType"
},
"gluc_PreferredStocksMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Preferred Stock [Member]"
}
}
},
"localname": "PreferredStocksMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"gluc_PreferredStocksParValuePerShare": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Preferred stock, par value per share]",
"verboseLabel": "Preferred stock, par value per share"
}
}
},
"localname": "PreferredStocksParValuePerShare",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails"
],
"xbrltype": "perShareItemType"
},
"gluc_PreferredStocksStatedValuePerShare": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Preferred stock, stated value per share"
}
}
},
"localname": "PreferredStocksStatedValuePerShare",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails"
],
"xbrltype": "perShareItemType"
},
"gluc_PrepaidExpensesPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Prepaid Expenses"
}
}
},
"localname": "PrepaidExpensesPolicyTextBlock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"gluc_ProvidesForQuarterlyPayments": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Provides for quarterly payments"
}
}
},
"localname": "ProvidesForQuarterlyPayments",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_ProvisionForIncomeTaxesDetails1Abstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "FEDERAL INCOME TAX (Details)"
}
}
},
"localname": "ProvisionForIncomeTaxesDetails1Abstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_ProvisionForIncomeTaxesDetailsNarrativeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "FEDERAL INCOME TAX (Details Narrative)"
}
}
},
"localname": "ProvisionForIncomeTaxesDetailsNarrativeAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_ReclassificationsPolicyTextblock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Reclassifications"
}
}
},
"localname": "ReclassificationsPolicyTextblock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"gluc_RecognizedRecoveryOfRetailerChargebacks": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Recognized recovery of retailer chargebacks"
}
}
},
"localname": "RecognizedRecoveryOfRetailerChargebacks",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/RecoveryOfRetailerChargebacksDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_RecoveryOfRetailerChargebacks": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 13.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Recovery of retailer chargebacks"
}
}
},
"localname": "RecoveryOfRetailerChargebacks",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"gluc_RecoveryOfRetailerChargebacksAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "RECOVERY OF RETAILER CHARGEBACKS"
}
}
},
"localname": "RecoveryOfRetailerChargebacksAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_RecoveryOfRetailerChargebacksTextblock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[RECOVERY OF RETAILER CHARGEBACKS]",
"verboseLabel": "RECOVERY OF RETAILER CHARGEBACKS"
}
}
},
"localname": "RecoveryOfRetailerChargebacksTextblock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/RecoveryOfRetailerChargebacks"
],
"xbrltype": "textBlockItemType"
},
"gluc_RegisteredMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Registered [Member]"
}
}
},
"localname": "RegisteredMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_ResignationsDescription": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Resignations description"
}
}
},
"localname": "ResignationsDescription",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"gluc_RetailerSalesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Retailer Sales"
}
}
},
"localname": "RetailerSalesMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetails"
],
"xbrltype": "domainItemType"
},
"gluc_SalesAndRetailerCustomerSales": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "[Sales and retailer customer sales]",
"verboseLabel": "Sales and retailer customer sales"
}
}
},
"localname": "SalesAndRetailerCustomerSales",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetails"
],
"xbrltype": "monetaryItemType"
},
"gluc_SalesAndRetailerCustomerSalesPercentage": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Sales and retailer customer sales percentage"
}
}
},
"localname": "SalesAndRetailerCustomerSalesPercentage",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetails"
],
"xbrltype": "percentItemType"
},
"gluc_SalesAndRetailerCustomerSalesTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Sales and retailer customer sales"
}
}
},
"localname": "SalesAndRetailerCustomerSalesTableTextBlock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsTables"
],
"xbrltype": "textBlockItemType"
},
"gluc_ScheduleOfPotentialDilutiveSecuritiesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of potential dilutive securities outstanding"
}
}
},
"localname": "ScheduleOfPotentialDilutiveSecuritiesOutstanding",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"gluc_ScheduleOfWarrantGrantsTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of warrant grants"
}
}
},
"localname": "ScheduleOfWarrantGrantsTableTextBlock",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"gluc_SharesIssuedForServicesShares": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Shares issued for services, shares]",
"verboseLabel": "Shares issued for services, shares"
}
}
},
"localname": "SharesIssuedForServicesShares",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"gluc_SharesIssuedForSettlementOfNotesPayableShares": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "[Shares issued for settlement of notes payable, shares]",
"verboseLabel": "Shares issued for settlement of notes payable, shares"
}
}
},
"localname": "SharesIssuedForSettlementOfNotesPayableShares",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"gluc_StockCompensationExpense": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 8.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Stock compensation"
}
}
},
"localname": "StockCompensationExpense",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"gluc_StockConversionDuringPeriodShares": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Conversion of preferred shares to common shares, shares"
}
}
},
"localname": "StockConversionDuringPeriodShares",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"gluc_StockConversionDuringPeriodValue": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Conversion of preferred shares to common shares, amount"
}
}
},
"localname": "StockConversionDuringPeriodValue",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"gluc_StockIssuedDuringPeriodSharesSettlementOfNotesPayable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Shares issued for settlement of notes payable, shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesSettlementOfNotesPayable",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"gluc_StockIssuedDuringPeriodValueSettlementOfNotesPayable": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Shares issued for settlement of notes payable, amount"
}
}
},
"localname": "StockIssuedDuringPeriodValueSettlementOfNotesPayable",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"gluc_StockholdersEquityDeficitDetailsNarrativeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STOCKHOLDERS DEFICIT (Details)"
}
}
},
"localname": "StockholdersEquityDeficitDetailsNarrativeAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_SubsequentEventsDetailsNarrativeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "SUBSEQUENT EVENTS (Details Narrative)"
}
}
},
"localname": "SubsequentEventsDetailsNarrativeAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_SummaryOfSignificantAccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
}
}
},
"localname": "SummaryOfSignificantAccountingPoliciesAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"
}
}
},
"localname": "SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_SummaryOfSignificantAccountingPoliciesPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"
}
}
},
"localname": "SummaryOfSignificantAccountingPoliciesPoliciesAbstract",
"nsuri": "http://glucosehealth.com/20220630",
"xbrltype": "stringItemType"
},
"gluc_TemporaryDifferences": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Temporary differences"
}
}
},
"localname": "TemporaryDifferences",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails"
],
"xbrltype": "monetaryItemType"
},
"gluc_TwoIndependentDirectorsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Two Independent Directors [Member]"
}
}
},
"localname": "TwoIndependentDirectorsMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"gluc_UnfinishedGoodsPackagingInventory": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Unfinished goods (packaging) inventory"
}
}
},
"localname": "UnfinishedGoodsPackagingInventory",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_UnpaidPrincipalBalanceOfConvertibleNotesPayable": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Unpaid principal balance"
}
}
},
"localname": "UnpaidPrincipalBalanceOfConvertibleNotesPayable",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"gluc_UnregisteredSharesOfCommonStockSharesIssued": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Unregistered shares of common stock shares issued"
}
}
},
"localname": "UnregisteredSharesOfCommonStockSharesIssued",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"gluc_WarrantsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Warrant [Member]"
}
}
},
"localname": "WarrantsMember",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"gluc_WebsiteDomainsNoncurrent": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 7.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"label": "Website domains"
}
}
},
"localname": "WebsiteDomainsNoncurrent",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"gluc_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
"nsuri": "http://glucosehealth.com/20220630",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "sharesItemType"
},
"srt_ConsolidatedEntitiesAxis": {
"auth_ref": [
"r88",
"r186",
"r191",
"r197",
"r318",
"r319",
"r320",
"r321",
"r350",
"r400"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Axis]"
}
}
},
"localname": "ConsolidatedEntitiesAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidatedEntitiesDomain": {
"auth_ref": [
"r88",
"r186",
"r191",
"r197",
"r318",
"r319",
"r320",
"r321",
"r350",
"r400"
],
"localname": "ConsolidatedEntitiesDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r181",
"r182",
"r183",
"r184",
"r203",
"r240",
"r260",
"r261",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r389",
"r390",
"r401",
"r402"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r176",
"r181",
"r182",
"r183",
"r184",
"r203",
"r240",
"r258",
"r260",
"r261",
"r285",
"r286",
"r287",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r389",
"r390",
"r401",
"r402"
],
"lang": {
"en-us": {
"role": {
"label": "Range [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r176",
"r181",
"r182",
"r183",
"r184",
"r203",
"r240",
"r258",
"r260",
"r261",
"r285",
"r286",
"r287",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r389",
"r390",
"r401",
"r402"
],
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r144",
"r346"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Axis]"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [
],
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
"auth_ref": [
"r36"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 11.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "Accounts payable and accrued expenses"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r145",
"r146"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts receivable, net of allowance for doubtful accounts"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableSale": {
"auth_ref": [
"r158"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease from sale of accounts receivable.",
"label": "Accounts receivable"
}
}
},
"localname": "AccountsReceivableSale",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedBonusesCurrent": {
"auth_ref": [
"r38"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Potential bonuses"
}
}
},
"localname": "AccruedBonusesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r38"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "[Accrued Liabilities, Current]",
"verboseLabel": "Accrued interest"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r21",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 14.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional paid in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r90",
"r91",
"r92",
"r289",
"r290",
"r291",
"r323"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-In Capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentOfWarrantsGrantedForServices": {
"auth_ref": [
"r66"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 6.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Adjustment for noncash service expenses paid for by granting of warrants.",
"label": "Warrants issued for services"
}
}
},
"localname": "AdjustmentOfWarrantsGrantedForServices",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r67"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
"label": "[Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities]",
"totalLabel": "Total adjustments"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_AdvertisingCostsPolicyTextBlock": {
"auth_ref": [
"r292"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for advertising cost.",
"label": "Advertising Expense"
}
}
},
"localname": "AdvertisingCostsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AdvertisingExpense": {
"auth_ref": [
"r293"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
"label": "Advertising expenses"
}
}
},
"localname": "AdvertisingExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
"auth_ref": [
"r26",
"r151",
"r157"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
"label": "Allowance for doubtful accounts",
"verboseLabel": "Allowance for doubtful accounts"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r66",
"r166",
"r171"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 9.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization of intangible asset"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r112"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Potential dilutive securities outstanding"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r12",
"r84",
"r130",
"r133",
"r139",
"r155",
"r186",
"r187",
"r188",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r318",
"r320",
"r327",
"r351",
"r353",
"r369",
"r380"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "[Assets]",
"totalLabel": "TOTAL ASSETS"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r7",
"r33",
"r84",
"r155",
"r186",
"r187",
"r188",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r318",
"r320",
"r327",
"r351",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 8.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "[Assets, Current]",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CURRENT ASSETS"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardDateAxis": {
"auth_ref": [
"r262",
"r263",
"r264",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by date or year award under share-based payment arrangement is granted.",
"label": "Award Date [Axis]"
}
}
},
"localname": "AwardDateAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardDateDomain": {
"auth_ref": [
"r262",
"r263",
"r264",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288"
],
"lang": {
"en-us": {
"role": {
"documentation": "Date or year award under share-based payment arrangement is granted."
}
}
},
"localname": "AwardDateDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r262",
"r263",
"r264",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
"auth_ref": [
"r2",
"r89",
"r126"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Business Description and Basis of Presentation [Text Block]",
"verboseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
}
}
},
"localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r3",
"r10",
"r68"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
"auth_ref": [
"r69"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
"label": "Cash and Cash Equivalents"
}
}
},
"localname": "CashAndCashEquivalentsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r62",
"r68",
"r74"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]",
"periodEndLabel": "CASH - END OF PERIOD",
"periodStartLabel": "CASH - BEGINNING OF PERIOD"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
"auth_ref": [
"r62",
"r328"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
"totalLabel": "NET INCREASE (DECREASE) IN CASH"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFDICInsuredAmount": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
"label": "Cash Federal Deposit Insurance Corporation"
}
}
},
"localname": "CashFDICInsuredAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r16",
"r18",
"r19",
"r81",
"r84",
"r104",
"r105",
"r106",
"r109",
"r110",
"r116",
"r117",
"r118",
"r155",
"r186",
"r191",
"r192",
"r193",
"r197",
"r198",
"r238",
"r239",
"r242",
"r246",
"r253",
"r327",
"r404"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetails1",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
"auth_ref": [
"r254"
],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
"label": "Warrants exercise price"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
"auth_ref": [
"r254"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
"label": "warrants were cancelled"
}
}
},
"localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ClassOfWarrantOrRightOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of warrants or rights outstanding.",
"label": "Held warrants"
}
}
},
"localname": "ClassOfWarrantOrRightOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r42",
"r374",
"r384"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "COMMITMENTS AND CONTINGENCIES"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r178",
"r179",
"r180",
"r185",
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "COMMITMENTS/CONTINGENCIES"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/CommitmentsContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r90",
"r91",
"r323"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common stock, par value per share",
"verboseLabel": "Common stock par value"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common stock, shares authorized",
"terseLabel": "Authorized common shares",
"verboseLabel": "Common stock, shares authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common stock, shares issued",
"terseLabel": "Common stock, shares issued",
"verboseLabel": "Common stock, shares issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r19",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common stock, shares outstanding",
"terseLabel": "Common stock, shares outstanding",
"verboseLabel": "Common stock shares outstanding"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r19",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 15.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common stock, value"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CompensationRelatedCostsPolicyTextBlock": {
"auth_ref": [
"r265"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
"label": "Share Based Compensation"
}
}
},
"localname": "CompensationRelatedCostsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConversionOfStockSharesIssued1": {
"auth_ref": [
"r71",
"r72",
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Conversion of common stock shares issued"
}
}
},
"localname": "ConversionOfStockSharesIssued1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ConvertibleDebt": {
"auth_ref": [
"r15",
"r371",
"r381"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
"label": "Convertible Notes"
}
}
},
"localname": "ConvertibleDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebtMember": {
"auth_ref": [
"r199",
"r200",
"r201",
"r203",
"r213",
"r214",
"r215",
"r219",
"r220",
"r221",
"r222",
"r223",
"r230",
"r231",
"r232",
"r233"
],
"lang": {
"en-us": {
"role": {
"documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
"label": "Convertible Debt [Member]"
}
}
},
"localname": "ConvertibleDebtMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConvertibleNotesPayableMember": {
"auth_ref": [
"r13",
"r370",
"r379",
"r396"
],
"lang": {
"en-us": {
"role": {
"documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
"label": "Convertible notes payable [Member]"
}
}
},
"localname": "ConvertibleNotesPayableMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
"auth_ref": [
"r17",
"r18",
"r249",
"r254",
"r255"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
"label": "Conversion of Preferred Stock shares into common shares"
}
}
},
"localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CostOfRevenue": {
"auth_ref": [
"r55",
"r84",
"r155",
"r186",
"r187",
"r188",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r327"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 3.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
"label": "Cost of revenues"
}
}
},
"localname": "CostOfRevenue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfRevenueAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "COST OF REVENUES"
}
}
},
"localname": "CostOfRevenueAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
"auth_ref": [
"r71",
"r73"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Warrant issued for purchase of common stock shares"
}
}
},
"localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_DebtConversionOriginalDebtAmount1": {
"auth_ref": [
"r71",
"r73"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Debt conversions principal amount"
}
}
},
"localname": "DebtConversionOriginalDebtAmount1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r80",
"r206",
"r207",
"r208",
"r209",
"r210",
"r211",
"r212",
"r217",
"r224",
"r225",
"r226",
"r236"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"verboseLabel": "NOTES PAYABLE"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayable"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r13",
"r14",
"r15",
"r83",
"r88",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r207",
"r213",
"r214",
"r215",
"r216",
"r218",
"r219",
"r220",
"r221",
"r222",
"r223",
"r230",
"r231",
"r232",
"r233",
"r337",
"r370",
"r371",
"r379"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r15",
"r227",
"r371",
"r379"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Notes"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentConvertibleConversionPrice1": {
"auth_ref": [
"r202",
"r228"
],
"lang": {
"en-us": {
"role": {
"documentation": "The price per share of the conversion feature embedded in the debt instrument.",
"label": "Conversion price per shares",
"verboseLabel": "Conversion price"
}
}
},
"localname": "DebtInstrumentConvertibleConversionPrice1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "perShareItemType"
},
"us-gaap_DebtInstrumentFaceAmount": {
"auth_ref": [
"r200",
"r230",
"r231",
"r336",
"r337",
"r338"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Face (par) amount of debt instrument at time of issuance.",
"label": "Outstanding balance"
}
}
},
"localname": "DebtInstrumentFaceAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
"auth_ref": [
"r40",
"r229",
"r336",
"r337"
],
"lang": {
"en-us": {
"role": {
"documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
"label": "Interest rate"
}
}
},
"localname": "DebtInstrumentInterestRateEffectivePercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r41",
"r83",
"r88",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r207",
"r213",
"r214",
"r215",
"r216",
"r218",
"r219",
"r220",
"r221",
"r222",
"r223",
"r230",
"r231",
"r232",
"r233",
"r337"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_DeferredRevenueRevenueRecognized1": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
"label": "Revenue"
}
}
},
"localname": "DeferredRevenueRevenueRecognized1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsValuationAllowance": {
"auth_ref": [
"r302"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
"label": "Net deferred tax asset valuation allowance"
}
}
},
"localname": "DeferredTaxAssetsValuationAllowance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Dividends": {
"auth_ref": [
"r256",
"r378"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
"label": "Dividends paid"
}
}
},
"localname": "Dividends",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DueFromRelatedParties": {
"auth_ref": [
"r20",
"r87",
"r189",
"r191",
"r192",
"r196",
"r197",
"r198",
"r345",
"r373",
"r385"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
"label": "Due from related parties"
}
}
},
"localname": "DueFromRelatedParties",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r112",
"r113"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Basic and Diluted Earnings/Loss per Common Share"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
"auth_ref": [
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Effective rate"
}
}
},
"localname": "EffectiveIncomeTaxRateContinuingOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails1"
],
"xbrltype": "percentItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
"auth_ref": [
"r85",
"r297",
"r311"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
"label": "Federal tax statutory rate"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails1"
],
"xbrltype": "percentItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STOCKHOLDERS EQUITY"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r47",
"r48",
"r49",
"r90",
"r91",
"r92",
"r94",
"r99",
"r101",
"r115",
"r156",
"r253",
"r256",
"r289",
"r290",
"r291",
"r307",
"r308",
"r323",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r341",
"r391",
"r392",
"r393"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAdjustmentOfWarrants": {
"auth_ref": [
"r66",
"r237"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
"label": "Fair value of warrant"
}
}
},
"localname": "FairValueAdjustmentOfWarrants",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueOfFinancialInstrumentsPolicy": {
"auth_ref": [
"r325",
"r326"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
"label": "Fair Value of Financial Instruments"
}
}
},
"localname": "FairValueOfFinancialInstrumentsPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"auth_ref": [
"r11",
"r170"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-lived intangible assets, accumulated amortization"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"auth_ref": [
"r167",
"r168",
"r170",
"r172",
"r366",
"r367"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by major type or class of finite-lived intangible assets.",
"label": "Finite-Lived Intangible Assets by Major Class [Axis]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"auth_ref": [
"r167",
"r169"
],
"lang": {
"en-us": {
"role": {
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
}
}
},
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainsLossesOnExtinguishmentOfDebt": {
"auth_ref": [
"r66",
"r234",
"r235"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 14.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
"label": "Loss on debt settlement",
"verboseLabel": "Loss on debt settlement"
}
}
},
"localname": "GainsLossesOnExtinguishmentOfDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r56"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 5.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r54",
"r84",
"r130",
"r132",
"r135",
"r138",
"r140",
"r155",
"r186",
"r187",
"r188",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r327"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 9.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "[Gross Profit]",
"totalLabel": "GROSS PROFIT"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
"auth_ref": [
"r173",
"r175"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
"label": "Recoverability of Long-Lived Assets"
}
}
},
"localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r51",
"r130",
"r132",
"r135",
"r138",
"r140",
"r368",
"r375",
"r377",
"r387"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 18.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]",
"totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STATEMENTS OF OPERATIONS"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r174",
"r177"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r177"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement."
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/CustomerConcentrationsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxAuthorityAxis": {
"auth_ref": [
"r299"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by tax jurisdiction.",
"label": "Income Tax Authority [Axis]"
}
}
},
"localname": "IncomeTaxAuthorityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxAuthorityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
}
}
},
"localname": "IncomeTaxAuthorityDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "FEDERAL INCOME TAX"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r85",
"r298",
"r300",
"r304",
"r309",
"r312",
"r314",
"r315",
"r316"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"verboseLabel": "FEDERAL INCOME TAX"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTax"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r86",
"r100",
"r101",
"r129",
"r296",
"r310",
"r313",
"r388"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 19.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "PROVISION FOR (BENEFIT FROM) INCOME TAXES"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeTaxPolicyTextBlock": {
"auth_ref": [
"r46",
"r294",
"r295",
"r300",
"r301",
"r303",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
"label": "Income Taxes"
}
}
},
"localname": "IncomeTaxPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxesPaidNet": {
"auth_ref": [
"r70"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
"label": "Cash paid for income taxes"
}
}
},
"localname": "IncomeTaxesPaidNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r65"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Increase (decrease) in accounts payable and accrued expenses"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r65"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "[Increase (Decrease) in Accounts Receivable]",
"negatedLabel": "(Increase) decrease in accounts receivable"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInventories": {
"auth_ref": [
"r65"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
"label": "[Increase (Decrease) in Inventories]",
"negatedLabel": "(Increase) decrease in inventory"
}
}
},
"localname": "IncreaseDecreaseInInventories",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Change in assets and liabilities"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_IntellectualPropertyMember": {
"auth_ref": [
"r317"
],
"lang": {
"en-us": {
"role": {
"documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
"label": "Intellectual Property [Member]"
}
}
},
"localname": "IntellectualPropertyMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical"
],
"xbrltype": "domainItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r61",
"r63",
"r70"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Cash paid for interest"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPayableCurrent": {
"auth_ref": [
"r38"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Outstanding interest balance"
}
}
},
"localname": "InterestPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryCashFlowPolicy": {
"auth_ref": [
"r75"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans.",
"label": "Cash Flow Reporting"
}
}
},
"localname": "InventoryCashFlowPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InventoryFinishedGoods": {
"auth_ref": [
"r27"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
"label": "Inventory finished goods"
}
}
},
"localname": "InventoryFinishedGoods",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r4",
"r31",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory",
"verboseLabel": "Total inventory"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryPolicyTextBlock": {
"auth_ref": [
"r9",
"r30",
"r77",
"r114",
"r160",
"r161",
"r162",
"r364"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
"label": "Inventory, Policy [Policy Text Block]",
"verboseLabel": "Inventory"
}
}
},
"localname": "InventoryPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InventoryRawMaterials": {
"auth_ref": [
"r29"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Raw materials inventory"
}
}
},
"localname": "InventoryRawMaterials",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWorkInProcess": {
"auth_ref": [
"r28"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
"label": "Work in process"
}
}
},
"localname": "InventoryWorkInProcess",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r37",
"r84",
"r134",
"r155",
"r186",
"r187",
"r188",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r319",
"r320",
"r321",
"r327",
"r351",
"r352"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 18.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "[Liabilities]",
"totalLabel": "TOTAL LIABILITIES"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r25",
"r84",
"r155",
"r327",
"r353",
"r372",
"r383"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "[Liabilities and Equity]",
"totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r8",
"r39",
"r84",
"r155",
"r186",
"r187",
"r188",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r319",
"r320",
"r321",
"r327",
"r351",
"r352",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 12.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "[Liabilities, Current]",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CURRENT LIABILITIES"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r62"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 16.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "[Net Cash Provided by (Used in) Financing Activities]",
"totalLabel": "Net cash provided by (used in) financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r62"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 17.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "[Net Cash Provided by (Used in) Investing Activities]",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r62",
"r64",
"r67"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 18.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "[Net Cash Provided by (Used in) Operating Activities]",
"totalLabel": "Net cash provided by (used in) operating activities",
"verboseLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "OPERATING ACTIVITIES:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r1",
"r44",
"r45",
"r49",
"r52",
"r67",
"r84",
"r93",
"r95",
"r96",
"r97",
"r98",
"r100",
"r101",
"r107",
"r130",
"r132",
"r135",
"r138",
"r140",
"r155",
"r186",
"r187",
"r188",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r324",
"r327",
"r376",
"r386"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 20.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "[Net Income (Loss) Attributable to Parent]",
"terseLabel": "Net loss",
"totalLabel": "NET LOSS ATTRIBUTABLE TO GLUCOSE HEALTH, INC.",
"verboseLabel": "Net income (loss)"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/StatementsOfCashFlows",
"http://glucosehealth.com/role/StatementsOfOperations",
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r95",
"r96",
"r97",
"r98",
"r102",
"r103",
"r108",
"r110",
"r130",
"r132",
"r135",
"r138",
"r140"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
"totalLabel": "NET LOSS AVAILABLE FOR COMMON STOCK HOLDERS"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "Recently Issued Accounting Standards Not Yet Adopted"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "NONCASH FINANCING ACTIVITIES:"
}
}
},
"localname": "NoncashInvestingAndFinancingItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r57"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 17.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "[Nonoperating Income (Expense)]",
"totalLabel": "Total other expense"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NotesPayableAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "NOTES PAYABLE"
}
}
},
"localname": "NotesPayableAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OperatingExpenses": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 10.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
"label": "[Operating Expenses]",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "OperatingExpenses",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "OPERATING EXPENSES"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r130",
"r132",
"r135",
"r138",
"r140"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 16.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "[Operating Income (Loss)]",
"totalLabel": "INCOME (LOSS) FROM OPERATIONS"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLossCarryforwards": {
"auth_ref": [
"r305"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
"label": "Net operating loss carryforwards",
"verboseLabel": "Net operating loss carry forward"
}
}
},
"localname": "OperatingLossCarryforwards",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails",
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLossCarryforwardsValuationAllowance": {
"auth_ref": [
"r302"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
"label": "[Operating Loss Carryforwards, Valuation Allowance]",
"negatedLabel": "Valuation allowance"
}
}
},
"localname": "OperatingLossCarryforwardsValuationAllowance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Assets"
}
}
},
"localname": "OtherAssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r58"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 11.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Interest income (expense)"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireIntangibleAssets": {
"auth_ref": [
"r59"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 12.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
"label": "[Payments to Acquire Intangible Assets]",
"negatedLabel": "Purchase of website domains"
}
}
},
"localname": "PaymentsToAcquireIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockDividendsAndOtherAdjustments": {
"auth_ref": [
"r103",
"r111"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 21.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
"label": "[Preferred Stock Dividends and Other Adjustments]",
"negatedLabel": "Dividends to preferred stock holders"
}
}
},
"localname": "PreferredStockDividendsAndOtherAdjustments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r18",
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred stock, par value per share"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred stock, shares authorized",
"verboseLabel": "Authorized preferred shares"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r18",
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred stock, shares issued",
"terseLabel": "Preferred stock, shares issued",
"verboseLabel": "Preferred stock, shares issued"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r18"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred stock, shares outstanding",
"terseLabel": "Preferred stock, shares outstanding",
"verboseLabel": "Preferred stock, shares outstanding"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r18",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 16.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred stock, value"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockVotingRights": {
"auth_ref": [
"r18",
"r254"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
"label": "Preferred Stock Voting Rights Description"
}
}
},
"localname": "PreferredStockVotingRights",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_PrepaidAdvertising": {
"auth_ref": [
"r6",
"r163",
"r165"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
"label": "Prepaid expenses for advertising services"
}
}
},
"localname": "PrepaidAdvertising",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseCurrent": {
"auth_ref": [
"r5",
"r32",
"r164",
"r165"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
"label": "Prepaid expenses"
}
}
},
"localname": "PrepaidExpenseCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
"auth_ref": [
"r60"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 13.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
"label": "Proceeds from preferred stock"
}
}
},
"localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 15.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
"label": "Payments on notes and loans payable"
}
}
},
"localname": "ProceedsFromRepaymentsOfNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 14.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
"label": "Payments on notes payable, related party"
}
}
},
"localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProfessionalFees": {
"auth_ref": [
"r397",
"r398"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 6.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
"label": "Professional fees"
}
}
},
"localname": "ProfessionalFees",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"auth_ref": [
"r53",
"r159"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfCashFlows": {
"order": 8.0,
"parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 7.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
"label": "Uncollectible receivables",
"verboseLabel": "Allowance for doubtful accounts"
}
}
},
"localname": "ProvisionForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows",
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyTransactionAxis": {
"auth_ref": [
"r259",
"r344",
"r345",
"r347"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of related party transaction.",
"label": "Related Party Transaction [Axis]"
}
}
},
"localname": "RelatedPartyTransactionAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionDomain": {
"auth_ref": [
"r259"
],
"lang": {
"en-us": {
"role": {
"documentation": "Transaction between related party."
}
}
},
"localname": "RelatedPartyTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_RelatedPartyTransactionsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "RELATED PARTY TRANSACTIONS"
}
}
},
"localname": "RelatedPartyTransactionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"auth_ref": [
"r342",
"r343",
"r345",
"r348",
"r349"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Related Party Transactions Disclosure [Text Block]",
"verboseLabel": "RELATED PARTY TRANSACTIONS"
}
}
},
"localname": "RelatedPartyTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r22",
"r256",
"r353",
"r382",
"r394",
"r395"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 13.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Accumulated deficit",
"verboseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r90",
"r91",
"r92",
"r94",
"r99",
"r101",
"r156",
"r289",
"r290",
"r291",
"r307",
"r308",
"r323",
"r391",
"r393"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueRecognitionPolicyTextBlock": {
"auth_ref": [
"r78",
"r79"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
"label": "Revenue Recognition"
}
}
},
"localname": "RevenueRecognitionPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Revenues": {
"auth_ref": [
"r50",
"r84",
"r127",
"r128",
"r131",
"r136",
"r137",
"r141",
"r142",
"r143",
"r155",
"r186",
"r187",
"r188",
"r191",
"r192",
"r193",
"r194",
"r195",
"r197",
"r198",
"r327",
"r377"
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
"label": "REVENUE, NET"
}
}
},
"localname": "Revenues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SaleLeasebackTransactionQuarterlyRentalPayments": {
"auth_ref": [
"r339",
"r340"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of the quarterly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.",
"label": "Quarterly payments"
}
}
},
"localname": "SaleLeasebackTransactionQuarterlyRentalPayments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
"auth_ref": [
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
"label": "Schedule of income tax expense"
}
}
},
"localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
"auth_ref": [
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
"label": "Schedule of deferred tax assets reconciliation"
}
}
},
"localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/FederalIncomeTaxTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
"auth_ref": [
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
"label": "Schedule of stockholders equity"
}
}
},
"localname": "ScheduleOfStockholdersEquityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SellingAndMarketingExpense": {
"auth_ref": [
],
"calculation": {
"http://glucosehealth.com/role/StatementsOfOperations": {
"order": 4.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
"label": "Selling and marketing"
}
}
},
"localname": "SellingAndMarketingExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SeriesAPreferredStockMember": {
"auth_ref": [
"r16",
"r18",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series A preferred stock.",
"label": "Series A Preferred Stock [Member]"
}
}
},
"localname": "SeriesAPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesBPreferredStockMember": {
"auth_ref": [
"r16",
"r18",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series B preferred stock.",
"label": "Series B Preferred Stock [Member]"
}
}
},
"localname": "SeriesBPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesCPreferredStockMember": {
"auth_ref": [
"r16",
"r18",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series C preferred stock.",
"label": "Series C Preferred Stock [Member]"
}
}
},
"localname": "SeriesCPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesDPreferredStockMember": {
"auth_ref": [
"r16",
"r18",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series D preferred stock.",
"label": "Series D Preferred Stock [Member]"
}
}
},
"localname": "SeriesDPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesEPreferredStockMember": {
"auth_ref": [
"r16",
"r18",
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series E preferred stock.",
"label": "Series E Preferred Stock [Member]"
}
}
},
"localname": "SeriesEPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r285"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"auth_ref": [
"r268"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
"label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number]",
"periodEndLabel": "Warrants exercisable"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"auth_ref": [
"r268"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
"label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price]",
"periodEndLabel": "Weighted-Average Exercise Price, Warrants exercisable"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
"auth_ref": [
"r273"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
"label": "Expired / cancelled"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Granted"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r266",
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]",
"periodEndLabel": "Outstanding, Ending Balance",
"periodStartLabel": "Outstanding, Beginning Balance"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r266",
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
"periodEndLabel": "Weighted-Average Exercise Price, Ending Balance",
"periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r262",
"r263",
"r264",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement."
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r271"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
"label": "Weighted-Average Exercise Price, Exercised"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r273"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
"label": "Weighted-Average Exercise Price, Expired / cancelled"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Weighted-Average Exercise Price, Granted"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharesIssued": {
"auth_ref": [
"r253"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
"label": "[Shares, Issued]",
"periodEndLabel": "Balance, shares",
"periodStartLabel": "Balance, shares"
}
}
},
"localname": "SharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShortTermDebtTypeAxis": {
"auth_ref": [
"r35"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of short-term debt arrangement.",
"label": "Short-Term Debt, Type [Axis]"
}
}
},
"localname": "ShortTermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShortTermDebtTypeDomain": {
"auth_ref": [
"r34"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
}
}
},
"localname": "ShortTermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r76",
"r89"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r16",
"r18",
"r19",
"r81",
"r84",
"r104",
"r105",
"r106",
"r109",
"r110",
"r116",
"r117",
"r118",
"r155",
"r186",
"r191",
"r192",
"r193",
"r197",
"r198",
"r238",
"r239",
"r242",
"r246",
"r253",
"r327",
"r404"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetails1",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r43",
"r47",
"r48",
"r49",
"r90",
"r91",
"r92",
"r94",
"r99",
"r101",
"r115",
"r156",
"r253",
"r256",
"r289",
"r290",
"r291",
"r307",
"r308",
"r323",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r341",
"r391",
"r392",
"r393"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/CustomerConcentrationsDetails",
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative",
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative",
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/StatementsOfShareholdersEquity",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetails1",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STATEMENTS OF CASH FLOWS"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "BALANCE SHEETS"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STATEMENTS OF SHAREHOLDERS' EQUITY"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r90",
"r91",
"r92",
"r115",
"r365"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/BalanceSheetsParenthetical",
"http://glucosehealth.com/role/CustomerConcentrationsDetails",
"http://glucosehealth.com/role/CustomerConcentrationsDetailsNarrative",
"http://glucosehealth.com/role/FederalIncomeTaxDetailsNarrative",
"http://glucosehealth.com/role/NotesPayableDetailsNarrative",
"http://glucosehealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative",
"http://glucosehealth.com/role/RelatedPartyTransactionsDetailsNarrative",
"http://glucosehealth.com/role/StatementsOfShareholdersEquity",
"http://glucosehealth.com/role/StockholdersDeficitDetails",
"http://glucosehealth.com/role/StockholdersDeficitDetails1",
"http://glucosehealth.com/role/StockholdersDeficitDetailsNarrative",
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative",
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
"label": "Shares issued for services, shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesIssuedForServices",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r18",
"r19",
"r253",
"r256"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Shares issued for cash received, shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r18",
"r19",
"r253",
"r256",
"r271"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Exercised"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersDeficitDetails1"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
"label": "Shares issued for services, amount"
}
}
},
"localname": "StockIssuedDuringPeriodValueIssuedForServices",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r18",
"r19",
"r253",
"r256"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Shares issued for cash received, amount"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r19",
"r23",
"r24",
"r84",
"r153",
"r155",
"r327",
"r353"
],
"calculation": {
"http://glucosehealth.com/role/BalanceSheets": {
"order": 17.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "[Stockholders' Equity Attributable to Parent]",
"periodEndLabel": "Balance, amount",
"periodStartLabel": "Balance, amount",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets",
"http://glucosehealth.com/role/StatementsOfShareholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STOCKHOLDERS' EQUITY"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/BalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r82",
"r239",
"r241",
"r242",
"r243",
"r244",
"r245",
"r246",
"r247",
"r248",
"r250",
"r251",
"r252",
"r256",
"r257",
"r322"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "STOCKHOLDER'S EQUITY"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StockholdersEquity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r335",
"r355"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r335",
"r355"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r335",
"r355"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEventsDetailsNarrative"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "SUBSEQUENT EVENTS"
}
}
},
"localname": "SubsequentEventsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventsTextBlock": {
"auth_ref": [
"r354",
"r356"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
"label": "Subsequent Events [Text Block]",
"verboseLabel": "SUBSEQUENT EVENTS"
}
}
},
"localname": "SubsequentEventsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SubsequentEvents"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SupplementalCashFlowElementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
}
}
},
"localname": "SupplementalCashFlowElementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/StatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_TradeAndOtherAccountsReceivablePolicy": {
"auth_ref": [
"r147",
"r148",
"r149",
"r150",
"r152",
"r154"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for accounts receivable.",
"label": "Accounts Receivable"
}
}
},
"localname": "TradeAndOtherAccountsReceivablePolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r119",
"r120",
"r121",
"r122",
"r123",
"r124",
"r125"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://glucosehealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
}
},
"unitCount": 5
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(16))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "270",
"URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r126": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "https://asc.fasb.org/topic&trid=2134479"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "11B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
},
"r162": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "330",
"URI": "https://asc.fasb.org/topic&trid=2126998"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.CC)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r185": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
},
"r2": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "https://asc.fasb.org/topic&trid=2122149"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3)(a)(2))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "40",
"SubTopic": "50",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "40",
"SubTopic": "50",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
},
"r236": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org/topic&trid=2208564"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "10",
"Topic": "480",
"URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r257": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(n)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b),(f(1))",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "35",
"Subparagraph": "(a)",
"Topic": "720",
"URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "35",
"Subparagraph": "(b)",
"Topic": "720",
"URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.4)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r316": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "https://asc.fasb.org/topic&trid=2144680"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "44",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "60",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "840",
"URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "840",
"URI": "https://asc.fasb.org/extlink&oid=123416376&loc=d3e50796-112755"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
},
"r349": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "850",
"URI": "https://asc.fasb.org/topic&trid=2122745"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r356": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "855",
"URI": "https://asc.fasb.org/topic&trid=2122774"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "330",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "340",
"Topic": "928",
"URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.10(3))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "405",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.3)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(13))",
"Topic": "946",
"URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Subparagraph": "(k)",
"Topic": "946",
"URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
"Topic": "946",
"URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 4))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r403": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r404": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402"
},
"r405": {
"Name": "Securities Act",
"Number": "7A",
"Publisher": "SEC",
"Section": "B",
"Subsection": "2"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(5))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(g)(6)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=123431969&loc=d3e4458-108587"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(k)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r89": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
}
},
"version": "2.1"
} |
